Discontinued ProductUnfortunately 1,9-Dideoxyforskolin (Cat. No. 5034) has been withdrawn from sale for commercial reasons.
Inactive analog of forskolin (Cat. No. 1099); does not activate adenylyl cyclase.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 378.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.64 mL||13.21 mL||26.42 mL|
|5 mM||0.53 mL||2.64 mL||5.28 mL|
|10 mM||0.26 mL||1.32 mL||2.64 mL|
|50 mM||0.05 mL||0.26 mL||0.53 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Wadler and Wiernik (1988) Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Res. 48 539 PMID: 2825978
McHugh and McGee (1986) Direct anesthetic-like effects of forskolin on the nicotinic acetylcholine receptors of PC12 cells. J.Biol.Chem. 261 3103 PMID: 3005280
Keywords: 1,9-Dideoxyforskolin, supplier, inactive, analogs, analogues, forskolin, adenylyl, adenylate, cyclases, Adenylyl, Cyclase, Adenylyl, Cyclase, Tocris Bioscience
Citations for 1,9-Dideoxyforskolin
Citations are publications that use Tocris products.
Currently there are no citations for 1,9-Dideoxyforskolin.
Literature in this Area
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.